Candidate: 7HP349

Type: Next-generation small molecule integrin activator

Status: 7 Hills on April 15 said it launched an evaluation of its lead compound 7HP349 as an oral adjuvant with a novel recombinant coronavirus vaccine, with the aim of initiating potential clinical testing in late 2020. The company is seeking collaboration partners with clinical-stage inactivated, live attenuated, or vectored coronavirus vaccines that may be enhanced with the adjuvant for elderly people and other at-risk patients, 7 Hills Pharma President and CEO Upendra Marathi said.


COVID-19: 200 Candidates and Counting

To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:

FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.

DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data.

KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.

TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.

GEN has also tagged the most common treatment types:

● ANTIVIRAL
● VAX
● ANTIBODY
● RNA

This site uses Akismet to reduce spam. Learn how your comment data is processed.